Tilray(TLRY) - 2026 Q2 - Quarterly Results

EXHIBIT 99.1 Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of $218 Million, Moves to Net Cash Position and Reaffirms Full-Year Adjusted EBITDA Guidance International Medical Cannabis Revenue Increases 36%; Canadian Adult-Use Cannabis Revenue Grows 6% Tilray Pharma Achieves Record Quarterly Revenue U.S. Federal Cannabis Rescheduling Expected to Unlock New Market Opportunity for Tilray Medical Expansion into the U.S. Strong Financial Position with $292 Million in Cash and Marketable Securities and ...